
|Videos|October 2, 2014
Dr. Rolfo Discusses the Potential Utility of Ceritinib
Author(s)Christian Rolfo, MD, PhD, MHBA
Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.
Advertisement
Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.
The most important potential for ceritinib is related to the activity seen in naïve patients. Rolfo says there is a possibility to use this agent early on.
There are also new combinations with ceritinib evaluating the potential to overcome resistance. Unfortunately, even with new promising agents, there is always a possibility of recurrence through mutations or transformations.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5



































